Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent
Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exa...
Gespeichert in:
Veröffentlicht in: | Toxicology and applied pharmacology 2014-12, Vol.281 (3), p.285-293 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 293 |
---|---|
container_issue | 3 |
container_start_page | 285 |
container_title | Toxicology and applied pharmacology |
container_volume | 281 |
creator | Li, Jason Z. Ke, Yuebin Misra, Hara P. Trush, Michael A. Li, Y. Robert Zhu, Hong Jia, Zhenquan |
description | Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells.
•Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1. |
doi_str_mv | 10.1016/j.taap.2014.10.012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22439932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X14003731</els_id><sourcerecordid>1647016773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7uzqC3iQgAge7LGSTv8DL7K4KqwugoK3UJ2uuBl6Om2SGdxn8KVN06PePBVUfl9V6vsYeyJgK0DUr3bbhDhvJQiVG1sQ8h7bCOjqAsqyvM82AEoUAO23M3Ye4w4AOqXEQ3YmK6VaUM2G_fpI5hYnF5MzPKbD4Chyb7nByVDghsaR713y5tZPQ3BYcJwG_unzjSj2NDhMNPBAg__J0SR3xOT8tOh7SliMOOMipJcc-ewTTcnhON7xyR9pzJPy0nUPfs9vj9gDi2Okx6d6wb5evf1y-b64vnn34fLNdWGqWqSi6mpsK5ItSEkKTdVa7CX0TdtZqyyIyvYtlHboEURui7LFCmxXqlzq2pYX7Nk61-erdTQuZQ-MnyYySUupyq4rZaZerNQc_I8DxaT3Li5-4ET-ELWoVZNTaJoyo3JFTfAxBrJ6Dm6P4U4L0EtUeqeXqPQS1dLLUWXR09P8Q5-t_Cv5k00Gnp8AjAZHG7JVLv7jOmhytiJzr1eOsmdHR2E5ibKtgwvLRYN3__vHb7MIso8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1647016773</pqid></control><display><type>article</type><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</creator><creatorcontrib>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</creatorcontrib><description>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells.
•Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2014.10.012</identifier><identifier>PMID: 25448047</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Activation, Metabolic - drug effects ; Animals ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - antagonists & inhibitors ; Antineoplastic Agents, Phytogenic - metabolism ; Antineoplastic Agents, Phytogenic - pharmacology ; BENZOQUINONES ; Beta-lapachone ; Biological and medical sciences ; Cancer cells ; CELL KILLING ; Cell Line, Tumor ; CHEMILUMINESCENCE ; Chemotherapy ; CLINICAL TRIALS ; ELECTRON SPIN RESONANCE ; Electron Transport Complex I - antagonists & inhibitors ; Electron Transport Complex I - metabolism ; Enzyme Inhibitors - pharmacology ; EPR ; HEPATOMAS ; Humans ; Indolequinones - pharmacology ; Medical sciences ; MELANOMAS ; Mice ; MITOCHONDRIA ; Mitochondria - drug effects ; Mitochondria - enzymology ; Mitochondria - metabolism ; Mitochondrial electron transport chain ; NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors ; NAD(P)H Dehydrogenase (Quinone) - metabolism ; Naphthoquinones - antagonists & inhibitors ; Naphthoquinones - metabolism ; Naphthoquinones - pharmacology ; Neoplasm Proteins - antagonists & inhibitors ; Neoplasm Proteins - metabolism ; Neoplasms - drug therapy ; Neoplasms - enzymology ; Neoplasms - metabolism ; NQO1 ; Oxidation-Reduction - drug effects ; OXIDES ; OXYGEN ; PEROXIDASES ; Pharmacology. Drug treatments ; PHOSPHATES ; Prodrugs - chemistry ; Prodrugs - metabolism ; Prodrugs - pharmacology ; RADICALS ; Reactive Oxygen Species - metabolism ; Reverse Transcriptase Inhibitors - chemistry ; Reverse Transcriptase Inhibitors - metabolism ; Reverse Transcriptase Inhibitors - pharmacology ; ROS ; Rotenone - pharmacology ; SUPEROXIDE DISMUTASE ; Toxicology</subject><ispartof>Toxicology and applied pharmacology, 2014-12, Vol.281 (3), p.285-293</ispartof><rights>2014 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</citedby><cites>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.taap.2014.10.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=29070081$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25448047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22439932$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jason Z.</creatorcontrib><creatorcontrib>Ke, Yuebin</creatorcontrib><creatorcontrib>Misra, Hara P.</creatorcontrib><creatorcontrib>Trush, Michael A.</creatorcontrib><creatorcontrib>Li, Y. Robert</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Jia, Zhenquan</creatorcontrib><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells.
•Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Activation, Metabolic - drug effects</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - antagonists & inhibitors</subject><subject>Antineoplastic Agents, Phytogenic - metabolism</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>BENZOQUINONES</subject><subject>Beta-lapachone</subject><subject>Biological and medical sciences</subject><subject>Cancer cells</subject><subject>CELL KILLING</subject><subject>Cell Line, Tumor</subject><subject>CHEMILUMINESCENCE</subject><subject>Chemotherapy</subject><subject>CLINICAL TRIALS</subject><subject>ELECTRON SPIN RESONANCE</subject><subject>Electron Transport Complex I - antagonists & inhibitors</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>EPR</subject><subject>HEPATOMAS</subject><subject>Humans</subject><subject>Indolequinones - pharmacology</subject><subject>Medical sciences</subject><subject>MELANOMAS</subject><subject>Mice</subject><subject>MITOCHONDRIA</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - enzymology</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondrial electron transport chain</subject><subject>NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors</subject><subject>NAD(P)H Dehydrogenase (Quinone) - metabolism</subject><subject>Naphthoquinones - antagonists & inhibitors</subject><subject>Naphthoquinones - metabolism</subject><subject>Naphthoquinones - pharmacology</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - metabolism</subject><subject>NQO1</subject><subject>Oxidation-Reduction - drug effects</subject><subject>OXIDES</subject><subject>OXYGEN</subject><subject>PEROXIDASES</subject><subject>Pharmacology. Drug treatments</subject><subject>PHOSPHATES</subject><subject>Prodrugs - chemistry</subject><subject>Prodrugs - metabolism</subject><subject>Prodrugs - pharmacology</subject><subject>RADICALS</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Reverse Transcriptase Inhibitors - chemistry</subject><subject>Reverse Transcriptase Inhibitors - metabolism</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>ROS</subject><subject>Rotenone - pharmacology</subject><subject>SUPEROXIDE DISMUTASE</subject><subject>Toxicology</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-KFDEQxoMo7uzqC3iQgAge7LGSTv8DL7K4KqwugoK3UJ2uuBl6Om2SGdxn8KVN06PePBVUfl9V6vsYeyJgK0DUr3bbhDhvJQiVG1sQ8h7bCOjqAsqyvM82AEoUAO23M3Ye4w4AOqXEQ3YmK6VaUM2G_fpI5hYnF5MzPKbD4Chyb7nByVDghsaR713y5tZPQ3BYcJwG_unzjSj2NDhMNPBAg__J0SR3xOT8tOh7SliMOOMipJcc-ewTTcnhON7xyR9pzJPy0nUPfs9vj9gDi2Okx6d6wb5evf1y-b64vnn34fLNdWGqWqSi6mpsK5ItSEkKTdVa7CX0TdtZqyyIyvYtlHboEURui7LFCmxXqlzq2pYX7Nk61-erdTQuZQ-MnyYySUupyq4rZaZerNQc_I8DxaT3Li5-4ET-ELWoVZNTaJoyo3JFTfAxBrJ6Dm6P4U4L0EtUeqeXqPQS1dLLUWXR09P8Q5-t_Cv5k00Gnp8AjAZHG7JVLv7jOmhytiJzr1eOsmdHR2E5ibKtgwvLRYN3__vHb7MIso8</recordid><startdate>20141215</startdate><enddate>20141215</enddate><creator>Li, Jason Z.</creator><creator>Ke, Yuebin</creator><creator>Misra, Hara P.</creator><creator>Trush, Michael A.</creator><creator>Li, Y. Robert</creator><creator>Zhu, Hong</creator><creator>Jia, Zhenquan</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20141215</creationdate><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><author>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Activation, Metabolic - drug effects</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - antagonists & inhibitors</topic><topic>Antineoplastic Agents, Phytogenic - metabolism</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>BENZOQUINONES</topic><topic>Beta-lapachone</topic><topic>Biological and medical sciences</topic><topic>Cancer cells</topic><topic>CELL KILLING</topic><topic>Cell Line, Tumor</topic><topic>CHEMILUMINESCENCE</topic><topic>Chemotherapy</topic><topic>CLINICAL TRIALS</topic><topic>ELECTRON SPIN RESONANCE</topic><topic>Electron Transport Complex I - antagonists & inhibitors</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>EPR</topic><topic>HEPATOMAS</topic><topic>Humans</topic><topic>Indolequinones - pharmacology</topic><topic>Medical sciences</topic><topic>MELANOMAS</topic><topic>Mice</topic><topic>MITOCHONDRIA</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - enzymology</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondrial electron transport chain</topic><topic>NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors</topic><topic>NAD(P)H Dehydrogenase (Quinone) - metabolism</topic><topic>Naphthoquinones - antagonists & inhibitors</topic><topic>Naphthoquinones - metabolism</topic><topic>Naphthoquinones - pharmacology</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - metabolism</topic><topic>NQO1</topic><topic>Oxidation-Reduction - drug effects</topic><topic>OXIDES</topic><topic>OXYGEN</topic><topic>PEROXIDASES</topic><topic>Pharmacology. Drug treatments</topic><topic>PHOSPHATES</topic><topic>Prodrugs - chemistry</topic><topic>Prodrugs - metabolism</topic><topic>Prodrugs - pharmacology</topic><topic>RADICALS</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Reverse Transcriptase Inhibitors - chemistry</topic><topic>Reverse Transcriptase Inhibitors - metabolism</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>ROS</topic><topic>Rotenone - pharmacology</topic><topic>SUPEROXIDE DISMUTASE</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jason Z.</creatorcontrib><creatorcontrib>Ke, Yuebin</creatorcontrib><creatorcontrib>Misra, Hara P.</creatorcontrib><creatorcontrib>Trush, Michael A.</creatorcontrib><creatorcontrib>Li, Y. Robert</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Jia, Zhenquan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jason Z.</au><au>Ke, Yuebin</au><au>Misra, Hara P.</au><au>Trush, Michael A.</au><au>Li, Y. Robert</au><au>Zhu, Hong</au><au>Jia, Zhenquan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2014-12-15</date><risdate>2014</risdate><volume>281</volume><issue>3</issue><spage>285</spage><epage>293</epage><pages>285-293</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells.
•Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>25448047</pmid><doi>10.1016/j.taap.2014.10.012</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-008X |
ispartof | Toxicology and applied pharmacology, 2014-12, Vol.281 (3), p.285-293 |
issn | 0041-008X 1096-0333 |
language | eng |
recordid | cdi_osti_scitechconnect_22439932 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | 60 APPLIED LIFE SCIENCES Activation, Metabolic - drug effects Animals Antineoplastic agents Antineoplastic Agents, Phytogenic - antagonists & inhibitors Antineoplastic Agents, Phytogenic - metabolism Antineoplastic Agents, Phytogenic - pharmacology BENZOQUINONES Beta-lapachone Biological and medical sciences Cancer cells CELL KILLING Cell Line, Tumor CHEMILUMINESCENCE Chemotherapy CLINICAL TRIALS ELECTRON SPIN RESONANCE Electron Transport Complex I - antagonists & inhibitors Electron Transport Complex I - metabolism Enzyme Inhibitors - pharmacology EPR HEPATOMAS Humans Indolequinones - pharmacology Medical sciences MELANOMAS Mice MITOCHONDRIA Mitochondria - drug effects Mitochondria - enzymology Mitochondria - metabolism Mitochondrial electron transport chain NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors NAD(P)H Dehydrogenase (Quinone) - metabolism Naphthoquinones - antagonists & inhibitors Naphthoquinones - metabolism Naphthoquinones - pharmacology Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - metabolism Neoplasms - drug therapy Neoplasms - enzymology Neoplasms - metabolism NQO1 Oxidation-Reduction - drug effects OXIDES OXYGEN PEROXIDASES Pharmacology. Drug treatments PHOSPHATES Prodrugs - chemistry Prodrugs - metabolism Prodrugs - pharmacology RADICALS Reactive Oxygen Species - metabolism Reverse Transcriptase Inhibitors - chemistry Reverse Transcriptase Inhibitors - metabolism Reverse Transcriptase Inhibitors - pharmacology ROS Rotenone - pharmacology SUPEROXIDE DISMUTASE Toxicology |
title | Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A39%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanistic%20studies%20of%20cancer%20cell%20mitochondria-%20and%20NQO1-mediated%20redox%20activation%20of%20beta-lapachone,%20a%20potentially%20novel%20anticancer%20agent&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Li,%20Jason%20Z.&rft.date=2014-12-15&rft.volume=281&rft.issue=3&rft.spage=285&rft.epage=293&rft.pages=285-293&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2014.10.012&rft_dat=%3Cproquest_osti_%3E1647016773%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1647016773&rft_id=info:pmid/25448047&rft_els_id=S0041008X14003731&rfr_iscdi=true |